Antares Pharma
Antares Pharma is a wholly owned subsidiary of Halozyme that develops and commercializes FDA-approved auto-injector drug delivery technologies, including the once-weekly XYOSTED testosterone enanthate injection for men with hypogonadism, distributed via an exclusive LifeMD telehealth partnership at approximately $249 per month.
- Company typePrivate
- Founded1979
- HeadquartersMinneapolis, United States
- Headcount51–100
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
Antares Pharma firmographics
Firmographics- Name
- Antares Pharma
- Legal name
- Antares Pharma, Inc.
- Website
- http://www.antarespharma.com/
- Company type
- Private
- Founded year
- 1979
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Short description
- Antares Pharma is a wholly owned subsidiary of Halozyme that develops and commercializes FDA-approved auto-injector drug delivery technologies, including the once-weekly XYOSTED testosterone enanthate injection for men with hypogonadism, distributed via an exclusive LifeMD telehealth partnership at approximately $249 per month.
- Ownership category
- akta.pro rank
Antares Pharma industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Auto-Injectors (Disposable & Reusable) (HLAHAIAB)
- akta.pro secondary industries
- Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Drug Delivery Connectivity, Sensors & Digital Add-Ons (Smart Caps/Companion Apps) (HLAHAIAM)
Keywords
Where Antares Pharma is headquartered
LocationHeadquarters
- HQ city
- Minneapolis
- HQ country
- United States
- HQ region
- North America
Markets served
Antares Pharma business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
Revenue model
- Direct-to-Patient Self-Pay Product Sales: Recurring monthly subscription-like revenue from direct-to-patient self-pay program for XYOSTED via telehealth partnership with LifeMD at approximately $249 per month, no insurance required.
- Parent Company Product Revenue (Halozyme Subsidiary): Antares operates as a wholly owned subsidiary of Halozyme, contributing to Halozyme's commercial portfolio of drug delivery products beyond the ENHANZE platform.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | XYOSTED Direct-to-Patient Self-Pay Program |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels2 records
Antares Pharma product offering
Product offeringCore offering
Antares Pharma develops and commercializes parenteral drug-device combination products built around proprietary auto-injector and multi-dose pen technologies. Its primary commercial product is XYOSTED, an FDA-approved once-weekly testosterone enanthate auto-injector for the treatment of hypogonadism, now being sold via a direct-to-patient self-pay telehealth program through LifeMD at approximately $249 per month including virtual consultations, lab-based diagnosis, and home delivery. As a wholly owned subsidiary of Halozyme, its drug delivery technology platform complements Halozyme's ENHANZE platform.
Product overview
Antares Pharma, a wholly owned subsidiary of Halozyme Therapeutics, contributes a focused portfolio of drug delivery devices and commercial pharmaceutical products built around self-administered injection technology. The core commercial offering is XYOSTED (testosterone enanthate) injection, an FDA-approved once-weekly testosterone auto-injector for hypogonadism, supported by an underlying Auto-Injector & Multi-Dose Pen Technologies platform inherited and integrated following Halozyme's acquisition of Antares Pharma. These offerings complement Halozyme's broader drug delivery portfolio (which also includes the ENHANZE® platform), extending parent company capabilities into auto-injector-based patient self-administration, with XYOSTED currently being commercialized through a direct-to-patient self-pay telehealth program launched in partnership with LifeMD.
Differentiator
Problem solved
Functional benefit
Products and services
- XYOSTED (testosterone enanthate) injection FDA-approved once-weekly testosterone enanthate auto-injector for the treatment of testosterone deficiency (hypogonadism) in adult men, commercialized via a direct-to-patient self-pay telehealth program with LifeMD that combines virtual consultations, lab-based diagnosis, and home delivery at approximately $249 per month in 37 U.S. states.
- Auto-Injector & Multi-Dose Pen Technologies Proprietary auto-injector and multi-dose pen drug delivery technology platform enabling patient self-administration of injectable therapies, including needle-assisted injection devices with reduced trigger force and integrated safety mechanisms. Used to underpin commercial products such as XYOSTED and integrated within Halozyme's drug delivery portfolio alongside ENHANZE.
Quantifiable outcome
- Direct-to-patient program launching in 37 U.S. states in July 2026
- +2 more outcomes
Companies that use Antares Pharma
Customer profileSegments2 records
Ideal customer profiles2 records
Antares Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Antares Pharma partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered flagship.
- LifeMD, Inc.flagshipExclusive telehealth co-marketing collaboration to launch a direct-to-patient self-pay program for XYOSTED (testosterone enanthate) injection in July 2026, initially in 37 U.S. states. LifeMD serves as the exclusive telehealth partner providing virtual consultations with licensed clinicians, laboratory-based diagnosis, and home delivery of the FDA-approved therapy through LifeMD's pharmacy at a transparent price of approximately $249 per month. Both companies will jointly invest in consumer education and promotional initiatives to expand awareness of testosterone deficiency and improve access to treatment.
- Halozyme, Inc.flagshipAntares Pharma is a wholly owned subsidiary of Halozyme, Inc. following an acquisition valued at over $900 million. Halozyme's strategic efforts include diversifying beyond its ENHANZE technology via acquisitions of Elektrofi and Antares Pharma to extend growth and mitigate patent expiration risks.
Scale indicators3 records
Recent moves7 records
Expansion highlights6 records
Antares Pharma competitors and assessment
Company assessmentBroad incumbents
- AbbVie: Global pharmaceutical leader with AndroGel, one of the most prescribed testosterone replacement therapies. Comparable as a TRT market incumbent with established payer relationships and large-scale commercialization capabilities.
- Ferring Pharmaceuticals: Global specialty biopharma with presence in testosterone therapy (e.g., AndroGel in certain markets) and reproductive health. Comparable as a broad incumbent operating in men's health and hormone replacement categories.
- Halozyme Therapeutics: Parent company of Antares Pharma following the $900M+ acquisition; operates the ENHANZE drug delivery platform. Comparable as the strategic acquirer/integrator of Antares' drug delivery technology and commercial portfolio.
- Insulet Corporation: Medical device company with the Omnipod insulin delivery system. Comparable as a drug delivery device company focused on patient self-administration technology and recurring consumables economics.
- West Pharmaceutical Services: Global leader in injectable drug containment and delivery components, including auto-injector and pen platforms. Comparable as an established player in the same drug delivery device category underpinning Antares' technology.
- Becton, Dickinson and Company (BD): Major medical technology company with a broad pharmaceutical systems portfolio including auto-injectors, prefilled syringes, and drug delivery devices. Comparable as a broad incumbent offering overlapping device capabilities and serving injectable therapeutics manufacturers.
Direct peers
- Endo International: Specialty pharmaceutical company with a strong men's health and testosterone portfolio (e.g., AndroGel competitor products). Directly comparable as a specialty pharma competitor in the TRT category where XYOSTED competes.
- Clarus Therapeutics: Specialty pharma focused on JATENZO, an oral testosterone replacement therapy. Directly comparable as a smaller specialty pharma competing in the U.S. TRT market with differentiated delivery format.
- Tolmar Pharmaceuticals: Specialty pharma with a testosterone franchise (e.g., Xyosted-equivalent injectable and other men's health products). Directly comparable as a specialty pharma peer in testosterone replacement therapy delivery.
Emerging players
- LifeMD: Telehealth platform and exclusive D2C partner for Antares' XYOSTED self-pay program. Comparable as the distribution/clinical-fulfillment partner enabling Antares' patient-facing channel in men's health.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Antares Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Antares Pharma leadership team
Management profileNumber of profiles
Profiles7 records
Antares Pharma funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Antares Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Antares Pharma
What does Antares Pharma do?
Antares Pharma develops and commercializes parenteral drug-device combination products built around proprietary auto-injector and multi-dose pen technologies. Its primary commercial product is XYOSTED, an FDA-approved once-weekly testosterone enanthate auto-injector for the treatment of hypogonadism, now being sold via a direct-to-patient self-pay telehealth program through LifeMD at approximately $249 per month including virtual consultations, lab-based diagnosis, and home delivery. As a wholly owned subsidiary of Halozyme, its drug delivery technology platform complements Halozyme's ENHANZE platform.
Is Antares Pharma a public or private company?
Antares Pharma is a private company. It is classified as corporate owned and is currently acquired.
When was Antares Pharma founded?
Antares Pharma was founded in 1979. It employs 51 to 100 people.
Where is Antares Pharma based?
Antares Pharma is headquartered in Minneapolis, United States, in the North America region.
How does Antares Pharma make money?
Two revenue lines are on record. Direct-to-Patient Self-Pay Product Sales are the primary driver. The others are parent Company Product Revenue (Halozyme Subsidiary).
Who are Antares Pharma's main competitors?
Broad incumbents on record are AbbVie, Ferring Pharmaceuticals, Halozyme Therapeutics, Insulet Corporation, West Pharmaceutical Services and Becton, Dickinson and Company (BD). Direct peers are Endo International, Clarus Therapeutics and Tolmar Pharmaceuticals. LifeMD is listed as an emerging player.
Does Antares Pharma have an API?
No public API is recorded for Antares Pharma.
What industry is Antares Pharma in?
Antares Pharma's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAHAIAB, Auto-Injectors (Disposable & Reusable), with a secondary code of HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 325412 and its SIC code is 2834.